智飞生物
(300122)
| 流通市值：281.16亿 | | | 总市值：475.89亿 |
| 流通股本：14.14亿 | | | 总股本：23.94亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,374,498,616.11 | 26,069,711,361.44 | 22,786,306,742.43 | 18,258,441,511.25 |
| 营业收入 | 2,374,498,616.11 | 26,069,711,361.44 | 22,786,306,742.43 | 18,258,441,511.25 |
| 二、营业总成本 | 2,434,178,574.47 | 23,192,418,166.64 | 19,685,884,775.99 | 15,281,723,020.21 |
| 营业成本 | 1,610,053,156.46 | 18,931,449,180.34 | 16,581,424,751.22 | 13,392,373,224.53 |
| 税金及附加 | 12,249,068.99 | 135,447,961.03 | 111,443,937.96 | 88,915,782.14 |
| 销售费用 | 429,766,771.06 | 2,650,685,785.78 | 1,936,199,475.15 | 1,115,557,033.68 |
| 管理费用 | 88,481,190.63 | 394,131,628.41 | 306,957,937.57 | 202,933,624.52 |
| 研发费用 | 227,359,676.59 | 971,365,516.55 | 695,547,263.17 | 461,348,505.91 |
| 财务费用 | 66,268,710.74 | 109,338,094.53 | 54,311,410.92 | 20,594,849.43 |
| 其中:利息费用 | 70,046,267.69 | 146,853,557.49 | 83,711,440.88 | 49,226,078.22 |
| 其中:利息收入 | 6,997,310.84 | 66,627,336.29 | 57,759,269.89 | 47,180,450.29 |
| 加:公允价值变动收益 | -1,928,650.82 | - | - | - |
| 资产处置收益 | 6,354,306.43 | 46,946.97 | 54,241.33 | 95,411.72 |
| 资产减值损失(新) | -38,336,112.34 | -39,539,833.44 | -26,397,568.74 | -12,005,862.6 |
| 信用减值损失(新) | -252,152,677.35 | -615,800,939.66 | -605,073,964.32 | -396,670,992.19 |
| 其他收益 | 13,012,999.37 | 41,812,908.21 | 15,706,250.03 | 10,985,925.73 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -332,730,093.07 | 2,263,812,276.88 | 2,484,710,924.74 | 2,579,122,973.7 |
| 加:营业外收入 | 22,162.3 | 69,496 | 38,091.88 | 38,090.48 |
| 减:营业外支出 | 409,212.47 | 10,190,202 | 6,794,354.14 | 6,456,906.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -333,117,143.24 | 2,253,691,570.88 | 2,477,954,662.48 | 2,572,704,157.62 |
| 减:所得税费用 | -27,976,549.96 | 235,213,056.97 | 327,331,724.54 | 338,384,793.01 |
| 六、净利润 | -305,140,593.28 | 2,018,478,513.91 | 2,150,622,937.94 | 2,234,319,364.61 |
| 持续经营净利润 | -305,140,593.28 | 2,018,478,513.91 | 2,150,622,937.94 | 2,234,319,364.61 |
| 归属于母公司股东的净利润 | -305,140,593.28 | 2,018,478,513.91 | 2,150,622,937.94 | 2,234,319,364.61 |
| (一)基本每股收益 | -0.13 | 0.84 | 0.9 | 0.93 |
| (二)稀释每股收益 | -0.13 | 0.84 | 0.9 | 0.93 |
| 九、综合收益总额 | -305,140,593.28 | 2,018,478,513.91 | 2,150,622,937.94 | 2,234,319,364.61 |
| 归属于母公司股东的综合收益总额 | -305,140,593.28 | 2,018,478,513.91 | 2,150,622,937.94 | 2,234,319,364.61 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-26 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |